Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
References | |
---|---|
Additional Infomation |
GSK1521498 has been used in trials studying the treatment of Obesity and Alcoholism.
|
Molecular Formula |
C24H20F2N4
|
---|---|
Molecular Weight |
402.44
|
Exact Mass |
326.134
|
CAS # |
1007573-18-3
|
Related CAS # |
GSK1521498 free base (hydrochloride);1007578-24-6;GSK1521498;1426543-84-1
|
PubChem CID |
24737629
|
Appearance |
White to off-white solid powder
|
LogP |
3.397
|
Hydrogen Bond Donor Count |
2
|
Hydrogen Bond Acceptor Count |
5
|
Rotatable Bond Count |
5
|
Heavy Atom Count |
30
|
Complexity |
537
|
Defined Atom Stereocenter Count |
0
|
InChi Key |
WIEDUMBCZQRGSY-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C24H20F2N4/c25-22-11-19(15-6-3-7-18(8-15)24-28-14-29-30-24)12-23(26)21(22)13-27-20-9-16-4-1-2-5-17(16)10-20/h1-8,11-12,14,20,27H,9-10,13H2,(H,28,29,30)
|
Chemical Name |
N-[[2,6-difluoro-4-[3-(1H-1,2,4-triazol-5-yl)phenyl]phenyl]methyl]-2,3-dihydro-1H-inden-2-amine
|
Synonyms |
GSK-1521498 GSK 1521498GSK1521498 GSK-1521498B
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~11.36 mg/mL (~28.23 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (4.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.4848 mL | 12.4242 mL | 24.8484 mL | |
5 mM | 0.4970 mL | 2.4848 mL | 4.9697 mL | |
10 mM | 0.2485 mL | 1.2424 mL | 2.4848 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT01366573 | COMPLETED | Drug: GSK1521498 Other: Placebo |
Alcoholism | GlaxoSmithKline | 2011-05-13 | Phase 1 |
NCT00976066 | COMPLETED | Drug: Part A Assessing GSK1521498 Drug: Part B Assessing GSK1521498 Drug: Part C Assessing Naltrexone |
Obesity | GlaxoSmithKline | 2009-06-15 | Phase 1 |
NCT00976066 | COMPLETED | Drug: Part A Assessing GSK1521498 Drug: Part B Assessing GSK1521498 Drug: Part C Assessing Naltrexone |
Obesity | GlaxoSmithKline | 2009-06-15 | Phase 1 |
NCT01195792 | COMPLETED | Drug: GSK1521498 Drug: Placebo |
Obesity | GlaxoSmithKline | 2010-09 | Phase 2 |
NCT00976105 | COMPLETED | Drug: Zolpidem or placebo - Hypnotic drug given for sleep disorders Drug: GSK1521498 or placebo |
Obesity | GlaxoSmithKline | 2009-09-22 | Phase 1 |